Painchek Ltd · ASX:PCK
Painchek — Corporate Update (January 2022)
27 slides from Painchek's corporate update, Jan 28, 2022
Slide 1: Quarterly Update January 2022
Quarterly Update January 2022 PHI LI P DAFFAS, PAI NCHEK LTD CEO & M D ASX:PCK 1 |
Slide 2: Corporate Overview
CORPORATE OVERVIEW PainChek provides Software-As-A-Service that uses AI for the detection of patient pain via video analysis • Targeting enterprise customers who have patients with an inability to communicate pain levels (e.g. dementia) Technology is clinically & commercially validated, has key regu
Slide 3: Our purpose is to give a voice to people who cannot reliably verbalise their pain
Our purpose is to give a voice to people who cannot reliably verbalise their pain 3 |
Slide 4: The Initial Size of the Problem
THE INITIAL SIZE OF THE PROBLEM 400M pre-verbal children 25-42% of hospital beds occupied by people with dementia 57M people living with dementia >150M expected by 2050 1. Ecology Communications Group. www.ecology.com/birth-death-rates 2. World Alzheimer Report 2016 3. Germossa et al. BMC Nursing (2
Slide 5: PainChek Strategic Pillars for 2022
PAINCHEK STRATEGIC PILLARS FOR 2022 CORE RAC FOCUS ON STRATEGIC NEW MARKET COMMERCIALISATION OF PRODUCT & GLOBAL EXPANSION INFANT APP MARKET ENTRIES • Implement 120,000 contracted • Initial target markets: • Build Home Care & Hospital beds across ANZ and transition - Post vaccination initial focus b
Slide 6: Where PainChek Started
WHERE PAINCHEK STARTED CARERS OF THOSE WHO CAN’T Australian SELF-REPORT Residential THEIR PAIN Aged Care 6 |
Slide 7: PainChek's Growing Presence in RACs Across Australia
PAINCHEK®’S GROWING PRESENCE IN RAC’S ACROSS AUSTRALIA 7 |
Slide 8: PainChek Proven Product and Business Model
PAINCHEK® PROVEN PRODUCT AND BUSINESS MODEL 1,509 Aged Care facilities contracted across 125,167 beds under contract in Aged four continents – up 71% year on year Care – up 76% year on year Figures based on December 2021 quarterly release 8
Slide 9: Projected ARR Covers Core PCK Australian Business Costs
PROJECTED ARR* COVERS CORE PCK AUSTRALIAN BUSINESS COSTS PainChek market penetration of 125,167 beds — projecting $5.73m ARR — post govt trial • Provides a validated platform for global expansion • Projected ARR would result in PCK covering the current Australian operational cost base • Outstanding
Slide 10: Transitioning Govt Funded Beds to Standard PCK Licenses
TRANSITIONING GOVT FUNDED BEDS TO STANDARD PCK LICENSES RAC beds by commercial, active RAC beds by commercial, active and yet to go live and yet to go live 10 |
Slide 11: PainChek UK & Sth Ireland Progress Gaining Momentum
PAINCHEK UK & STH IRELAND PROGRESS GAINING MOMENTUM “ We have rolled PainChek out across the Orchard portfolio, initially focusing on our dementia communities, however once we observed such amazing results it was agreed to launch in all of our care UK market traction Government funding Launching int
Slide 12: PainChek - Building a Global Digital Capability
PAINCHEK - BUILDING A GLOBAL DIGITAL CAPABILITY Engage Implement Clinical Support & Sell Train Utility Insights • eLearning platform and certification • Training videos • Online workshop training 1:1 and classroom • App Store downloads (Apple & Google) • Security protected • Online integration 12 I
Slide 13: PainChek - Building a Global Digital Capability
PAINCHEK – BUILDING A GLOBAL DIGITAL CAPABILITY Engage Implement Clinical Support & Sell Train Utility Insights • Integration with customer medical records • Secure digital storage and privacy of data • Secure user access • Detailed usage reporting • Data reports help care homes meet accreditation s
Slide 14: Integration Partners
INTEGRATION PARTNERS – From one integration partner in 2018 to 12 in Australia, 5 in UK/EU, 4 in NZ and 1 in Canada PainChek works with aged care management and Point of care PainChek assessments on a resident are medication management systems covering more automatically transmitted to the care mana
Slide 15: PainChek Infant App - Regulatory Cleared for Sale in Multiple Markets
PAINCHEK INFANT APP – REGULATORY CLEARED FOR SALE IN MULTIPLE MARKETS* • PainChek’s world first facial recognition technology to assess pre-verbal infant procedural pain through a 3-second AI based video analysis of the face • CE & TGA clearance achieved Q2 CY21 • Clinical study published in Lancet
Slide 16: Initial Infant Market Opportunity in Regulatory Cleared Markets
INITIAL INFANT MKT OPPORTUNITY IN REGULATORY CLEARED MARKETS Canada – Europe (EU) • 360,000 4 Million infants/births in infants/births in 2020 (including UK) 2020 UK • ~620,000 infants/births US / FDA * in 2020 • 3.75M infants/births in ANZ 2020 • 300,000 • Assessing CDS infants/births in submission
Slide 17: PainChek Infant Initial Target Markets
PAINCHEK INFANT INITIAL TARGET MARKETS 1. Post vaccination 2. Post operative 3. Partnerships & licensing Approx. 140 million children Pain associated with Targeting global born globally each year surgical procedures (e.g. therapeutic companies including 300,000 in Australia post tonsillectomy), & pr
Slide 18: PainChek's Potential as a Key Tool in Infant COVID-19 Vaccinations
PAINCHEK’S POTENTIAL AS A KEY TOOL IN INFANT COVID -19 VACCINATIONS THE MKT CHALLENGE THE PCK OPPORTUNITY A HOME BASED PAIN VACCINATION FOR YOUNGER AGE GROUPS ASSESSMENT FOR PARENTS Global Government COVID-19 Helping to address concerns that vaccination programme can cause parental vaccine shifting
Slide 19: Infant Go To Market Strategy
INFANT GO TO MARKET STRATEGY Utility Business Model Post vaccination B2B Enterprise Healthcare Professional baseline and (Subscription) -GPs follow up -Vax Centres assessment -Pharmacy Post Vax training in clinical Ongoing monitoring in the home B2C Consumer environment Direct to New Consumers take
Slide 20: How PainChek Infant Can Support HCPs & Parents
HOW PAINCHEK® INFANT CAN SUPPORT HCP’s & PARENTS BETTER MANAGE POST VACCINATION PAIN FOR INFANTS 1. 2. 3. 4. Infant receives the PainChek Infant made Parent is educated on If pain persists, vaccine, most often available to immuniser signs/symptoms of parent has been resulting in acute, to document p
Slide 21: Next Steps - Infants Roll Out
NEXT STEPS – INFANTS ROLL OUT Liaise with Governments & Infant Vaccine Roll out Building relationships/partnerships with: • Large pharma • Diagnostics • Clinical research Extend App utility to two years olds Build multi-dimensional Infant tool Expand DTC reach for Infant and Adult 21 |
Slide 22: New Market Expansion - Home Care & Partnerships
NEW MARKET EXPANSION – HOME CARE & PARTNERSHIPS • 1st reseller & integration partnership with MPS/Sigma, a major healthcare medication management provider • MPS is providing a world first end-to-end medication management solution, Medisphere, with PainChek as its integrated pain management tool • Bu
Slide 23: The Team
THE TEAM Philip Daffas Prof. Jeff Hughes Andrew Hoggan Iain McAdam CEO & Managing Chief Scientific Head of Operations CFO Director, MBA, BSc Officer PhD, MPS Philip is a highly accomplished global Jeff is a professor in the School of Pharmacy, Andy is a Psychologist, management Iain has over 20 year
Slide 24: The Board
THE BOARD John Murray Chairman John Murray Philip Daffas Ross Harricks Adam Davey Non-Exec Chair CEO & Managing Director Non-Exec Director Non-Exec Director 25 years in tech & Venture Philip is a highly accomplished Senior global medical device Corporate finance executive Capital. Founder of Technol
Slide 25: Corporate Summary
CORPORATE SUMMARY Financial information Share price (27 January 2022) A$0.051 Shares on issue 1,132.6m Market capitalisation A$57.8m Cash (31 December 2021) A$6.5m Unlisted options/performance rights 58.8m Debt Nil Top shareholders % Peters Investments Proprietary Ltd 9.98% Board & key staff 4.3% 25
Slide 26: PainChek Strategic Pillars for 2022
PAINCHEK STRATEGIC PILLARS FOR 2022 CORE RAC FOCUS ON STRATEGIC NEW MARKET COMMERCIALISATION OF PRODUCT & GLOBAL EXPANSION INFANT APP MARKET ENTRIES • Implement 120,000 contracted • Initial target markets: • Build Home Care & Hospital beds across ANZ and transition - Post vaccination initial focus b
Slide 27: Our purpose is to give a voice to people who cannot reliably verbalise their pain
Our purpose is to give a voice to people who cannot reliably verbalise their pain 27 |